View : 15 Download: 0

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

Title
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression
Authors
Byung C.Y.Ju H.K.Kim T.-H.Kwang C.K.Um S.-H.Young S.K.Kwan S.L.Byung H.H.Chae Y.C.Han J.-Y.Soo H.R.Haak C.K.Kwan S.B.Seong G.H.Kim B.-I.Cho M.Yoo K.Lee H.-J.Jae S.H.Yun S.K.Lee Y.-S.Choi S.-K.Lee Y.-J.Yang J.-M.Park J.-W.Lee M.-S.Kim D.-G.Chung Y.-H.Cho S.-H.Choi J.-Y.Kweon Y.-O.Heon Y.L.Jeong S.-H.Yoo H.-W.Lee H.-S.
Ewha Authors
유권김태헌
SCOPUS Author ID
유권scopus; 김태헌scopus
Issue Date
2007
Journal Title
Hepatology
ISSN
0270-9139JCR Link
Citation
vol. 46, no. 4, pp. 1041 - 1048
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Clevudine is a pyrimidine analog with potent and sustained antiviral activity against HBV. In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of antiviral response for 24 weeks after cessation of dosing in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (e-CHB). We randomized a total of 86 patients (3:1) to receive clevudine 30 mg (n = 63) or placebo (n = 23) daily for 24 weeks. We followed patients for an additional 24 weeks after withdrawal of treatment. The median changes in HBV DNA from baseline were -4.25 and -0.48 log10 copies/mL at week 24 in the clevudine and placebo groups, respectively (P < 0.0001). Viral suppression in the clevudine group was sustained after withdrawal of therapy, with 3.11 log10 reduction at week 48. At week 24 and week 48, 92.1% and 16.4% of patients in the clevudine group had undetectable serum HBV DNA levels by Amplicor PCR assay (<300 copies/mL). The proportion of patients who achieved ALT normalization was 74.6% and 33.3% in the clevudine and placebo groups at week 24, respectively (P = 0.0006). ALT normalization in the clevudine group was well-maintained during the post-treatment follow-up period. The incidence of adverse events was similar in the 2 groups. No resistance to clevudine was detected during treatment. Conclusion: A 24-week clevudine therapy was well-tolerated and showed potent and sustained antiviral effect without evidence of viral resistance in e-CHB patients. However, treatment for longer than 24 weeks would be needed to achieve durable remission. Copyright © 2007 by the American Association for the Study of Liver Diseases.
DOI
10.1002/hep.21800
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE